UCB touts an­oth­er pso­ri­a­sis win, this time over Cosen­tyx, as they look to break in­to packed mar­ket

Long a qui­et play­er in the R&D game, UCB made a splash last fall when they an­nounced that their ex­per­i­men­tal pso­ri­a­sis drug bimek­izum­ab had de­feat­ed J&J’s block­buster Ste­lara in a Phase III tri­al. It was the first of three Phase II­Is meant to launch the can­di­date in­to a crowd­ed mar­ket dom­i­nat­ed by some of the in­dus­try’s biggest drug­mak­ers. The sec­ond an­nounce­ment came two months lat­er with a win over Ab­b­Vie’s Hu­mi­ra.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER